MMP9 and prostate carcinoma: Employing siRNA-based partial target modulation in DU145 and PC3 prostate carcinoma cells, inhibition of EMT-related gene expression (with downregulation of MMP9, MMP2, VIM, and SNAI1, among others) and suppression of migration and metastasis were assessed in vitro.